Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CRT 2018: Late-Breakers Feature Sapien MR, Selution DCB, Low-Risk TAVR, and Radial Access PCI

Executive Summary

The late-breaking trials presented at the 2018 CRT Conference in Washington, DC, March 3-6 included new clinical data on novel drug-eluting coronary stents, endovascular peripheral vascular interventions, and transcatheter heart valve devices, plus a major trial comparing transfemoral and transradial coronary interventions.

Advertisement

Related Content

Results Recap: CRT In DC Features New Biotronik Stent Data, Encouraging TAVR Low-Risk Data; Ablative Systems’ Alcohol Renal Denervation
2018 Earnings Spotlight: Transcatheter Valve Repair Remains Big Drivers For Medtronic, Edwards, Abbott
TAVR Update: Edwards Delays European Launch Of Sapien 3 Ultra; New Medtronic CoreValve Data
Global Approvals Analysis: LivaNova, Abbott, Medtronic, Boston Scientific Lead List Of January Cardio Approvals
Starts & Stops: 2017 Finishes With Progress For Edwards, Stalled Trials For Boston Scientific
Edwards Adds To Wide Range Of Approaches To Mitral Repair

Topics

Advertisement
UsernamePublicRestriction

Register

MT122321

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel